18 results about "Toxoid" patented technology

A lipid-containing composition, by weight, includes phospholipids, and one or more of vegetable oil, medium-chain triglycerides, antioxidants, and sodium oleate. It has been verified that the various compositions provided by this invention competitively capture protein-bound toxoids in the blood, thereby achieving the purpose of clearing protein-bound toxoids from the blood, especially for patients with liver failure, and also alleviating oxidative stress in patients during dialysis treatment.

The present invention relates to immunogenic compositions that comprise a Clostridioides difficile toxoid A and / or a C. difficile toxoid B, and an adjuvant, and methods of use thereof. The present invention further relates to methods for eliciting an enhanced immune response in a human against a C. difficile infection. The methods include administering to the human an effective dose of an immunogenic composition, which includes a C. difficile toxoid and an adjuvant, wherein the composition is administered two or three times.

The present application relates to a kind of high crosslinking macroporous resin of adsorbing macromolecular toxin and its preparation method, belong to blood perfusion adsorption resin technical field.The preparation method described in the present application includes: (1) the styrene monomer, polyvinyl crosslinking agent, pore-forming agent and initiator are mixed as oil phase, dispersant, surfactant, salt and pure water are mixed as water phase, oil phase is dispersed in water phase under stirring condition to prepare O / W emulsion, suspension polymerization reaction is carried out by heating, polystyrene-based white ball is obtained, washing, extraction, drying;(2) polystyrene-based white ball is swelled, then fatty aldehyde and lewis acid catalyst are added, reaction is carried out, and the product is washed and dried.The high crosslinking macroporous resin described in the present application has larger specific surface area, excellent biocompatibility, can adsorb protein binding class toxin such as macromolecular toxin in blood;The present application simultaneously provides preparation method, green and environmental protection.

The invention relates to recombinant III-type collagen as well as a preparation method and application thereof, and belongs to the technical field of genetic engineering. The invention provides a recombinant micromolecular collagen derived from III-type human collagen, and the recombinant micromolecular collagen is successfully expressed; an expression system of the micromolecular collagen and a preparation method of the micromolecular collagen are established, and an exclusive chassis cell and a recombinant vector are constructed. The micromolecular collagen is excellent in transdermal absorption and biological activity, and the expression yield of the micromolecular collagen is greatly increased through the expression system or method; the scheme provided by the invention not only avoids the risk of high cost and foreign protein residue caused by in-vitro protease digestion production of collagen, but also does not generate toxoid, and is very beneficial to subsequent production.

The invention belongs to the technical field of blood purification, and discloses a protein binding toxoid adsorbent, a preparation method and application. The adsorbent is porous resin with a quaternary ammonium salt structure, and the porous resin is obtained by carrying out suspension polymerization reaction on a styrene monomer and a co-crosslinking agent; the co-crosslinking agent comprises divinyl benzene and methacrylamide ethylene glycol methyl ether. The adsorbent has excellent adsorption performance and blood compatibility, and effectively solves the problem of accumulation of protein binding toxoid in the body of a chronic kidney disease patient. During preparation, firstly, raw materials such as styrene monomers, divinyl benzene, methacrylamide ethylene glycol methyl ether and the like are subjected to suspension polymerization to prepare microspheres, and then tetramethyl diamine is grafted to the surfaces of the microspheres through quaternization reaction. The preparation method is simple in process, mild in reaction condition and high in safety. The adsorbent disclosed by the invention can be applied to the fields of preparation of blood perfusion devices and clinical removal of protein binding toxoid, and has a wide clinical application prospect.

A lipid-containing composition, by weight, includes phospholipids, and one or more of vegetable oil, medium-chain triglycerides, antioxidants, and sodium oleate. It has been verified that the various compositions provided by this invention competitively capture protein-bound toxoids in the blood, thereby achieving the purpose of clearing protein-bound toxoids from the blood, especially for patients with liver failure, and also alleviating oxidative stress in patients during dialysis treatment.

This invention provides a means to inactivate the inherent toxicity of tetanus toxin and produce a safe and effective vaccine. [Solution] This specification provides engineered non-catalytic, non-toxic tetanus toxin variants and methods for using such engineered tetanus toxin variants as low-dose prophylactic vaccines that are more effective than non-toxic and their respective chemically inactivated toxoids. In addition, this specification provides conjugate vaccine carriers containing engineered tetanus toxin variants and methods for using such conjugate vaccines to induce a T-cell-dependent immunomemory response that can target a broad range of microbial pathogens as a single vaccine.

The application provides an anti-TROP2 antibody-drug conjugate or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the heavy chain of the anti-TROP2 antibody comprises at least one non-natural amino acid residue as shown in formula (I). The application also provides a preparation method and uses of the antibody-drug conjugate. The anti-TROP2 antibody and auristatin toxin are conjugated at a specific site in the application, so that a brand new antibody-drug conjugate is obtained, which has very excellent biological activity and is obviously superior to existing similar products, and the preparation process is simple and easy to control.

The application discloses a zearalenone toxin separation and ionization integrated mass spectrometry ionization device and application thereof, wherein the mass spectrometry ionization device comprises a sample carrier table, the sample carrier table comprises a support frame, a detachable extraction element, one end of the extraction element is connected with the support frame, the extraction element comprises a conductive layer formed by stainless steel, an extraction layer located on at least part of the surface of the conductive layer, the extraction layer is formed by a covalent organic polymer, wherein the covalent organic polymer is formed by 1, 3, 5-tri (4-aminophenyl) benzene (TAPB) and 1, 3, 5-triformylphloroglucinol (Tp) through a polymerization reaction, and a high-voltage power supply connected with the extraction element. The extraction layer of the extraction element of the device is formed by a covalent organic polymer, the extraction layer has selective adsorption capacity for zearalenone mycotoxins, and the adsorption capacity is strong.

The invention relates to the technical field of marine toxin analysis, and particularly discloses a multi-class marine toxin sample analysis method suitable for shellfish matrices, and the method comprises the following steps: weighing and labeling; one-step acidification organic solvent extraction; carrying out same-bed segmented solid phase enrichment; carrying out chromatography-mass spectrometry on the polar components; performing chromatography-mass spectrometry analysis on hydrophobic components; carrying out normalized quantification and quality control confirmation; according to the method, different bonding phases such as reverse phase and ion exchange are combined into the same bed or a composite medium, and segmented recovery is performed according to polarity through sequential elution, so that various toxins obtain more targeted elution conditions. According to the strategy, the enrichment degree of a target object in a corresponding elution section can be enhanced, a large number of matrix interferents can be dispersed into different sections, subsequent chromatographic separation and mass spectrometric detection are facilitated, and therefore the influence of the matrix effect on quantification is reduced from the source.

A composition including modified ASFV outer-membrane protein antigen mutants (termed dominant negative toxoid antigens) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated response capable of neutralizing unmodified proteins found on infectious outer-membrane-laden ASFV virions. A method for the treatment and / or prevention of ASFV by administering a dominant negative toxoid antigenic composition to animals, thereby averting RBC aggregation caused by the antigen and concurrently treating and / or preventing ASFV. An ASFV vaccine composition including dominant negative toxoid antigens. A composition including dominant negative toxoid antigens in conjunction together and in conjunction with antigens derived from capsid-based proteins, which collectively target both lysogenic and lytic viral replication cycles, thereby achieving optimal immune stimulatory protection. Methods and compositions allowing for differentiation of infected from vaccinated animals (DIVA).

The invention belongs to the technical field of biological control, and particularly relates to an insecticidal gene separated from bacillus HSY144, protein and application thereof. Through whole genome sequencing and bioinformatics mining, six novel nematode killing genes, namely p71, chr431, chr611, chr2000, chr3401 and chr6103, are obtained on the basis of bacillus HSY144 cloning. Sequence and evolution analysis discovers that the protein P71 and the protein Chr431 belong to a Cry14 toxoid (Cry14-like), the protein Chr611 belongs to a Cry65 toxoid (Cry65-like), the protein Chr2000, the protein Chr3401 and the protein Chr6103 belong to a Cry21 toxoid (Cry21-like). Different from traditional crystal proteins, the six proteins do not generate parasporal crystals after being expressed, but the nematicidal activity of the six proteins is equivalent to or better than that of Cry5B. Therefore, the technical scheme provided by the invention not only can be used for preventing and treating the plant parasitic nematodes, but also provides a novel gene resource for biological prevention and treatment and resistance treatment of the plant parasitic nematodes.

This invention proposes a graphyne / gold nanocomposite material, its preparation method, and its application. The graphyne / gold nanocomposite material comprises graphyne and gold nanoparticles loaded on its surface. Graphyne can enrich the gold nanoparticles, and the gold nanoparticles loaded on the graphyne can generate a localized surface plasmon resonance effect, thereby providing a SERS signal response. The substrate of this invention exhibits good SERS signal response to dyes and plant toxins, and the substrate enhancement effect is stable and highly reproducible, ensuring the accuracy and reliability of the detection results. This invention also proposes the application of the above-mentioned graphyne / gold nanocomposite material as a surface-enhanced Raman scattering substrate for detecting isoxazole / tryptamine toxins in mushrooms. This enables rapid detection of psilocybin and amatoxins in complex matrices of fungal samples; it can be used for rapid screening of highly poisonous mushrooms and their products in food safety, showing significant application prospects.

Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.

A composition including modified ASFV outer-membrane protein antigen mutants (termed dominant negative toxoid antigens) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated response capable of neutralizing unmodified proteins found on infectious outer-membrane-laden ASFV virions. A method for the treatment and / or prevention of ASFV by administering a dominant negative toxoid antigenic composition to animals, thereby averting RBC aggregation caused by the antigen and concurrently treating and / or preventing ASFV. An ASFV vaccine composition including dominant negative toxoid antigens. A composition including dominant negative toxoid antigens in conjunction together and in conjunction with antigens derived from capsid-based proteins, which collectively target both lysogenic and lytic viral replication cycles, thereby achieving optimal immune stimulatory protection. Methods and compositions allowing for differentiation of infected from vaccinated animals (DIVA).

The invention relates to the technical field of aquatic product quality safety, in particular to a saxitoxin risk formation chain characterization monitoring system, which comprises a data acquisition module, a data processing module, a data processing module and a display module, the risk chain association module is used for constructing a multi-factor toxin association mechanism model, analyzing and quantifying influence weights of environmental factors through a causal inference algorithm and a random forest weight, and identifying key regulation points and threshold values of toxin synthesis; the risk chain mechanism analysis module carries out deduction through a digital twin simulation platform and a dynamic Bayesian network, simulates the dynamic change of a toxin anabolism pathway under different environment scenes, and obtains a risk formation chain and a risk change rule thereof; and the risk monitoring and intervention module constructs a global risk prediction model to obtain a risk level, obtains an emergency scheme from the emergency decision library according to the risk level and the toxin type, and performs intervention according to the emergency scheme. Therefore, the problems of monitoring lag, unknown causality, low intervention efficiency and the like are solved.

In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and / or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and / or toxin B is sustained.

A toxin derivative represented by formula (I) or a stereoisomer and pharmaceutically acceptable salt thereof, and a use thereof for preparing a drug conjugate. A drug conjugate and a use thereof. The toxin derivative is linked to an auristatin toxin by adjusting the structure of a linker to form a novel linker-effector small molecule, achieving excellent biological activity and efficient endocytosis when used for preparing a drug conjugate, and facilitating the expansion of the design, production and application of auristatin conjugates. X-L 1-A-NH(CH 2CH 2O) n-L 2-D (formula (I))